Eli Lilly jumps as pill leads to 7.9% weight loss in late-stage trial

Shares of drugmaker Eli Lilly LLY.N rise 11.3% to $817.99 premarket

Company says its oral drug orforglipron led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial

U.S.-listed shares of Lilly's obesity drug rival Novo Nordisk NOVOb.CO down 3.8%

Other weight-loss drug developers such as Viking Therapeutics VKTX.O down 4.6% and Amgen AMGN.O down 2%

Up to last close, LLY shares down 4.8%, VKTX down 41.2% YTD